InMed Prognostics

InMed Prognostics is a health care startup that aims to revolutionize neurological assessments by harnessing the power of AI and ML-driven MRI insights to provide better clinical support. Their flagship product, Neuroshield, utilizes advanced technology to combine MRI images, clinical reports, and psychological assessments for generating automated, quantified reports. This not only enhances the efficiency of neuroradiologists, neuro physicians, and psychiatrists but also aids in forming clinical impressions for various neurological disorders.

Founded in 2018, InMed Prognostics recently secured a significant milestone with a $2.13M Seed Round investment from Exxora on 12 December 2022. This injection of capital is expected to fuel the company's growth and further advancements in their AI and ML-based MRI tool. With their dedication to leveraging technology for improving neurological care, InMed Prognostics is poised to make a significant impact in the healthcare industry.